Exagen Stock
Exagen Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- John Aballi
- Employees
- 216
- Market cap
- $187 M
- IPO
- 19/09/2019
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis,…
Exagen stock: price history
1D
-9.8%
1W
-8.3%
1M
-0.8%
6M
+150.6%
YTD
+27.0%
1Y
-34.4%
2Y
+174.7%
5Y
-38.9%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~58% stronger price swings than usual
Ask the agents about Exagen
Analyst assessment of Exagen
PRICE TARGET LOW
US$8.00
CONSENSUS
US$8.00
MEDIAN
US$8.00
PRICE TARGET HIGH
US$8.00
0
STRONG BUY
10
BUY
0
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 13/10/2026
Exagen stock metrics
P/E
-9.41
P/B
15.27
EV/EBITDA
-16.61
RETURN ON EQUITY
-26.2%
NET MARGIN
-16.0%
DEBT/EQUITY
2.09
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
57.1%
FLOAT SHARES
13,835,576
AVG. DAILY VOLUME (30D)
325,936
Insider transactions (SEC)
Black Jeffrey G.
Black Jeffrey G.
Institutional holders
Comparable stocks
Frequently asked questions about Exagen stock
What does Exagen do?
Exagen Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is John Aballi, the company employs around 216 people.
The IPO was on 19/09/2019; the stock trades on NASDAQ under the ticker XGN.
What do analysts say about Exagen stock?
10 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$8.00, ranging from US$8.00 to US$8.00, with a median of US$8.00.
This is an external assessment, not a statement by Market Jury.
When does Exagen report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 58% stronger than usual.
Does Exagen pay a dividend?
No, Exagen currently does not pay a dividend.
Which stocks are comparable to Exagen?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get Exagen stock analyzed?
Clicking "Analyze stock" lets five strategies assess Exagen against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.